Find a specific notice:

A revocation to this notice was published on 14 March 2022, Notice No. 2022-go928.

Notice Type
Departmental
Notice Title

Specification of COVID-19 Vaccines Under the COVID-19 Public Health Response Act 2020 for the Purpose of the Air Border Order

Publication Date
25 Feb 2022

Tags

Notices Health COVID-19 COVID-19 Public Health Response Act COVID-19 Public Health Response (Air Border) Order 2021

Notice Number

2022-go678
Title
View PDF
File Type and Size
PDF (30 KB)

Pursuant to section 5(3)(b) of the COVID-19 Public Health Response Act 2020, I, Dr Ashley Bloomfield, Director-General of Health, hereby declare that the doses of each COVID-19 vaccine or combination of COVID-19 vaccines specified in this notice are required for a person to be “vaccinated” for the purposes of clause 13 of the COVID-19 Public Health Response (Air Border) Order 2021 (“Order”) other than for General traveller (A) persons and General traveller (B) persons pursuant to the Order. A combination of vaccine doses will meet the definition where this is the accepted schedule in the place of vaccination.

The most recent dose of the schedule of vaccination must have been administered at least 14 days prior to the person’s direct or connecting flight to New Zealand.

For the purposes of clause 13 of the Order other than for persons designated General traveller (A) persons and General traveller (B) persons pursuant to the Order vaccinated means being vaccinated against COVID-19 with at least one of the following complete vaccination courses (meaning the combination of COVID-19 vaccine and number of doses in each line):

  • Pfizer/BioNTech (Comirnaty, Tozinameran, BNT162b2) 2 doses.
  • AstraZeneca (Oxford/AstraZeneca, Vaxzevria, AZD1222, ChAdOx1 nCoV-19) 2 doses.
  • AstraZeneca (Covishield, Serum Institute of India formulation) 2 doses.
  • Moderna (Spikevax, mRNA-1273) 2 doses.
  • Janssen / Johnson & Johnson (Janssen COVID-19 Vaccine, Ad26.COV2.S1, JNJ-78436735) 1 dose.
  • Sinopharm, Beijing (BBIBP-CorV, BiBP vaccine, Covilo) 2 doses.
  • Sinovac (CoronaVac, PiCoVacc) 2 doses.
  • Bharat Biotech (Covaxin, BBV152) 2 doses.
  • Novovax (Nuvaxovid, (NVX-CoV2373) 2 doses.
  • Covovax (Serum Institute of India Novovax) 2 doses.
  • Zifivax (Anhui Zhifei Longcom, ZF2001, ZF-UZ-VAC-2001) 2 doses.
  • Corbevax (Biological E. (BioE) Limited, BECOV2D, BECO2A, BioE COVID-19) 2 doses.
  • CanSino (Convidecia, PakVac, Ad5-nCoV) 2 doses.
  • Abdala (Center for Genetic Engineering and Biotechnology, CIGB-66) 2 doses.
  • KoviVac (Chumakov Centre) 2 doses.
  • EpiVacCorona (Federal Budgetary Research Institution State Research Center of Virology and Biotechnology (FBRI), VECTOR) 2 doses.
  • Aurora-Cov (Federal Budgetary Research Institution State Research Center of Virology and Biotechnology (FBRI) EpiVacCorona-N) 2 doses.
  • Sputnik Light (Gamaleya Research Institute of Epidemiology and Microbiology) 1 dose.
  • Sputnik V (Gamaleya Research Institute of Epidemiology and Microbiology, Gam-COVID-Vac) 2 doses.
  • Tukovac (Health Institutes of Turkey, ERUCOV-VAC) 2 doses.
  • Soberana 02 (Instituto Finlay de Vacunas Cuba, FINLAY-FR-2, Pasteurcovac) 2 doses.
  • Soberana Plus (Instituto Finlay de Vacunas Cuba, FINLAY-FR-1A (as a 3rd dose after 2 doses of Soberana 02).
  • Qazvac (Khazakstan Research Institute for Biological Safety Problems, RIBSP QazCovid-in) 2 doses.
  • MVC COVID-19 vaccine (Medigen Vaccine Biologics Corporation, MVC-COV1901) 2 doses.
  • KCONVAC (Minhai Biotechnology Co (Beijing), KconecaVac, Minhai COVID-19 Vaccine) 2 doses.
  • Recombinant SARS-CoV-2 Vaccine (CHO Cell) (National Vaccine and Serum Institute (China), NVSI-06-08) Recombinant COVID-10 Vaccine (CHO cell, NVSI-06-08) 3 doses.
  • FAKHRAVAC (Organization of Defensive Innovation and Research (Iran), MIVAC) 2 doses.
  • Rasi Cov Pars (Razi Vaccine and Serum Research Institute (Iran)) 3 doses.
  • COVIran Barekat (Shifa Pharmed Industriall Co(Iran) B1V1-CovIran) 2 doses.
  • Sinopharm (Wuhan) (WIBP-CorV, Inactivated (Vero Cells) 2 doses.
  • Takeda (TAK-919) (Moderna formulation) 2 doses.
  • SpikoGen (Vaxine/CinnaGen Co (Australia), COVAX-19 2 doses.
  • Zydus Cadila (ZyCoV-D) 3 doses.

For the avoidance of doubt, vaccinated for the purposes of clause 13 of the COVID-19 Public Health Response (Air Border) Order 2021 (“Order”) for persons designated General traveller (A) persons and General traveller (B) persons pursuant to the Order means vaccinated in accordance with the Specification of COVID-19 Vaccines under section 5(3) of the COVID-19 Public Health Response Act 2020 Notice.

However, for General traveller (A) and General traveller (B) persons, the most recent dose of the schedule of vaccination must have been administered at least 14 days prior to the person’s direct or connecting flight departing for New Zealand.

This notice comes into effect at 11.59pm on 27 February 2022.

Dated at Wellington this 25th day of February 2022.

Dr ASHLEY BLOOMFIELD, Director-General of Health.